FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
News|Articles|October 20, 2026
Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know
Author(s)Alex Biese
Fact checked by: By ONN Staff
Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.
Advertisement
Advertisement
The FDA approval of tucatinib (Tukysa) plus trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer adds an oral, chemotherapy-free option after induction, and it shifts much of the day-to-day work of monitoring liver function, managing diarrhea, and supporting at-home adherence to oncology nurses and PAs.
Related to this article
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.
Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.
Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.
For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.
Advertisement
Advertisement